The expansion will see the firm occupy 20,151sq ft of laboratory and office space at 155 Brook Drive, which is part of the Science Vale Enterprise Zone.
The company, which initially occupied c7,800 sq ft in the Schrödinger Building is increasing capacity for its technology teams by expanding to 21,000 sq ft of facilities.
The financing was led by Oxford Sciences Innovation, with participation from Borealis Ventures, Perivoli Innovations, and other institutional and individual investors.
The medical device company focused on point of care asthma diagnosis and management released a trading update for the six months ended 30 June 2021.
The class II labs answer the significant demand from science and tech start-ups and SMEs for lab space in Oxford’s world-leading life sciences cluster in Headington.
The Woodstock based company was awarded B Corp certification after demonstrating strict compliance to the rigorous requirements of this globally-recognised mark.
The studies will allow the company to assess the ability of its next-generation vaccine to boost the immune response against current and potential future strains of COVID-19.
The 745 sq ft molecular diagnostics research and quality control lab will support its customers in developing improved molecular diagnostics for COVID-19 and other pathogens.
The combination expands Exscientia’s capabilities by enabling high content evaluation of individual patient biology in primary tumour tissues rather than artificial cell lines or animal models.
Biotech start-up, DJS Antibodies, is the second company to move into the newly converted class II laboratory space at The Oxford Trust’s Wood Centre for Innovation.
The arrival of G7 health ministers to Oxford on Thursday 03 June will shine a spotlight on Oxfordshire’s considerable achievements in the life sciences sector.
The company has reported robust financial performance in its 2021 unaudited revenues of at least £9.0 million compared to £2.1 million in the 2020 audited accounts.